Last reviewed · How we verify
NCT05631015
Artificial Intelligence for Determination of Gastroscopy Surveillance Intervals
trial testing AI recongnize disease and generate recommendations in Helicobacter Pylori Infection in 2,000 participants. Status unknown.
31 October 2022
Quick facts
| Lead sponsor | Xiuli Zuo |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 1 January 2012 |
| Primary completion | 31 October 2022 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- AI recongnize disease and generate recommendations
Conditions studied
- Helicobacter Pylori Infection — all drugs for Helicobacter Pylori Infection →
- Atrophic Gastritis — all drugs for Atrophic Gastritis →
- Intestinal Metaplasia — all drugs for Intestinal Metaplasia →
- Low Grade Intraepithelial Neoplasia — all drugs for Low Grade Intraepithelial Neoplasia →
Sponsor
Xiuli Zuo
Who can join
Adults 18 to 80, any sex, with Helicobacter Pylori Infection or Atrophic Gastritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to develop and validate a clinical decision support system based on automated algorithms. This system can use natural language processing to extract data from patients' endoscopic reports and pathological reports, identify patients' disease types and grades, and generate guidelines based follow-up or treatment recommendations
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05631015
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Helicobacter Pylori Infection
Currently open trials in the same condition.
- NCT07285096 — P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication · recruiting
- NCT07358130 — Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy · NA · recruiting
- NCT07165444 — Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatme · NA · recruiting
- NCT06929962 — VA Dual Sequential Therapy · Phase 4 · recruiting
- NCT06959368 — Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication · Phase 4 · recruiting
Other Xiuli Zuo trials
Trials by the same sponsor.
- NCT06772064 — Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating. · NA · recruiting
- NCT06731023 — Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extreme · not yet recruiting
- NCT06751212 — Observation on the Efficacy of Radiofrequency Ablation for Patients With Moderate to Severe Gastric Atrophy With Enteros · not yet recruiting
- NCT05810805 — Measurement and Analysis of Gas Composition in Digestive Tract · unknown
- NCT05126121 — Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05631015 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiuli Zuo
- Last refreshed: 30 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05631015.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing